As of Friday close, Bionano Genomics Inc.’s (NASDAQ:BNGO) stock was down -$0.02, moving down -1.74 percent to $1.13. The average number of shares traded per day over the past five days has been 6,578,460 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0700 fall in that time frame. In the last twenty days, the average volume was 6,792,380, while in the previous 50 days, it was 6,820,694.
Since last month, BNGO stock retreated -30.67%. Shares of the company fell to $1.1000 on 03/17/23, the lowest level in the past month. A 52-week high of $4.35 was reached on 02/02/23 after having rallying from a 52-week low of $1.10. Since the beginning of this year, BNGO’s stock price has dropped by -22.60% or -$0.3300, and marked a new high 8 times. However, the stock has declined by -74.02% since its 52-week high.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
BNGO stock investors should be aware that Bionano Genomics Inc. (BNGO) stock had its last reported insider trading activity 215 days ago on Aug 15. Linney Yvonne, the Director of the company, disposed of 20,000 shares for $3.62 on Aug 15. It resulted in a $72,402 divestment by the insider. BARKER DAVID L added 10,000 shares at an average price of $1.60 on May 16. The insider now owns 13,894 shares following the transaction.
The stock’s beta is 2.33. Besides these, the trailing price-to-sales (P/S) ratio of 13.50, the price-to-book (PB) ratio of 1.19.
In the three months ended September 29, Bionano Genomics Inc.’s quick ratio stood at 3.60, while its current ratio was 4.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.01, and the total debt-to-equity ratio was 0.02. On the profitability front, the trailing twelve-month gross margin is 16.90% percent. Based on annual data, BNGO earned $5.95 million in gross profit and brought in $27.8 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BNGO’s revenue rose 23.36% to $7.22 million during the quarter, while net income inched up to $8.22 million. While analysts expected Bionano Genomics Inc. to report -$0.11 quarterly earnings, the actual figure was -$0.11 per share. During the quarter, the company generated -$34.77 million in EBITDA. The liabilities of Bionano Genomics Inc. were 58.1 million at the end of its most recent quarter ended September 29, and its total debt was $10.39 million. The value of shareholders’ equity is $306.24 million.
This quick technical analysis looks at Bionano Genomics Inc.’s (BNGO) price momentum. With a historical volatility rate of 39.12%, the RSI 9-day stood at 25.93% on 17 March.
With respect to its five-day moving average, the current Bionano Genomics Inc. price is down by -5.83% percent or -$0.0700. At present, BNGO shares trade -26.14% below its 20-day simple moving average and -47.20% percent below its 100-day simple moving average. However, the stock is currently trading approximately -24.16% below its SMA50 and -34.68% below its SMA200.
Stochastic coefficient K was 17.39% and Stochastic coefficient D was 27.82%, while ATR was 0.0899. Given the Stochastic reading of 8.70% for the 14-day period, the RSI (14) reading has been calculated as 30.26%. As of today, the MACD Oscillator reading stands at -0.0678, while the 14-day reading stands at -0.1100.
Scotiabank launched its rating on Bionano Genomics Inc. (NASDAQ: BNGO) to a Sector outperform in a note to investors on January 05, 2023. Bionano Genomics Inc. (BNGO) has been rated Buy by analysts. According to 0 brokerage firms, BNGO is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Bionano Genomics Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $6.00, the current consensus forecast for the stock is $3.00 – $7.50. Based on these forecasts, analysts predict Bionano Genomics Inc. (BNGO) will achieve an average price target of $5.10.